

## Personal Information



## Richard Hendry de Boer

**Address:** Epworth-Freemasons Hospital  
Epworth Hospital Richmond  
Peter MacCallum Cancer Institute  
St Vincent's Private Hospital

**Country:** Australia

## Curriculum Vitae

### Current Appointments: Consultant Medical Oncologist

- 1) Epworth-Freemasons Hospital, Clarendon St, East Melbourne, 3002
- 2) Epworth Hospital Richmond, Bridge Rd, Richmond 3121
- 3) Peter MacCallum Cancer Institute, Victorian Comprehensive Cancer Centre, Grattan St, Parkville 3052
- 4) St Vincent's Private Hospital, Gipps St, East Melbourne 3002

### Education

1977 - 1982    Secondary School:    Caulfield Grammar School  
Graduated 1st (Dux) in class

1983 - 1988    Medical School:    M.B, B.S - University of Melbourne  
Honours, Graduated 4th in class of 180.

1994-1996    Post Graduate training in Medical Oncology

### Specialist Certification

Fellowship, Royal Australasian College of Physicians

Successfully completed written and oral exams at first attempt - 1993

Accepted as Fellow of the Royal Australasian College of Physicians December 1996.

### Professional Societies

Royal Australasian College of Physicians  
Australian Medical Association (AMA)  
Clinical Oncology Society of Australia (COSA)

Medical Oncology Group of Australia (MOGA)

Cancer Trials Australia

American Society of Clinical Oncology (ASCO)

International Association for the Study of Lung Cancer (IASLC)

### **Additional Responsibilities**

Head of Breast Cancer Trials group – Cancer Trials Australia – 2010-2014

Deputy Head of Lung Cancer Group – Victorian Cancer Council – 2009-2011

Head of Lung Cancer Group – Victorian Cancer Council – 2012-2014

Chair of Epworth-Freemasons Medical Oncology/Haematology Advisory Committee 2009-ongoing

Member of Epworth-Freemasons Medical Advisory Committee 2009-ongoing (currently Chair)

Member of Epworth Hospitals Group Medical Advisory Committee (Group MAC) 2012-ongoing

Member of Epworth Hospitals Cancer Services Executive 2014-ongoing

Editorial Board Member – Journal of Bone Oncology 2011- ongoing

### **International Trial Steering Committees**

FACE Trial (Letrozole vs Anastrozole in ESBC)

ZOFAST Trial (Zoledronic Acid plus Letrozole in ESBC)

AMG706 Study (AMG706 plus taxane in MBC)

ZEAL Trial (Vandetanib plus Pemetrexed in met NSCLC)

BOLERO-6 Trial (Everolimus plus Exemestane vs Capecitabine in HR resistant metBC)

### **Honours Obtained in University of Melbourne Medical School**

Final Year	Surgery	H2B
	Paediatrics	H2A
	Medicine	H2B
	Obstetrics and Gynaecology	H2B

(Elizabeth Pennington Award for ‘Contribution to Student Affairs’ at Royal Melbourne Hospital)

5th Year	Paediatrics	H2B
	Obstetrics and Gynaecology	H2B

4th Year      Medicine and Surgery      H2A  
(Ken Grice Award for top 4th year Medical Student at Royal Melbourne Hospital)

3rd Year      Pharmacology      H1  
                Pathology      H2B  
                Microbiology      H2A  
                Metabolism and Endocrinology H1

2nd Year      Anatomy      H1  
(Prosector in Anatomy [top 6 student], University of Melbourne Medical School)  
                Biochemistry      H1  
                Neuroscience      H2B  
                Physiology      H2A  
                Behavioural Science      H2B

1st Year      Anatomy      H1  
                Biology      H1  
                Chemistry      H1  
                Physiology      H2A  
                Physics      H2B

*(H1 - 1st Class Honours; H2 - 2nd Class Honours; H2A - 2nd Class Honours: Division A  
H2B - 2nd Class Honours: Division B)*

### **Employment Positions Held**

1989	Internship	
	Royal Melbourne Hospital, Victoria	
	Infectious Diseases	3 months
	General Medicine/ Surgery	6 months
	Anaesthetics & Emergency	3 months
1990/91	Resident Medical Officer	
	Royal Melbourne Hospital, Victoria	
	Anaesthetics / Cardiology	6 months

	Radiation Oncology / Relieving	6 months
	General Medicine	6 months
	Neurology/Intensive Care	6 months
1992/3	General Medical Registrar	
	Royal Melbourne Hospital, Victoria	
	Medical Oncology (Bone Marrow Transplant Service)	6 months
	Stroke Service \ General Medicine	18 months
1994/5	Medical Oncology Registrar	
	Royal Melbourne Hospital: Haematology	6 months
	Western Hospital: Medical Oncology	6 months
	Royal Melbourne Hospital: Bone Marrow Transplant	6 months
	Austin Hospital: Medical Oncology	6 months
1996	Clinical Research Fellow	
	Centre for Developmental Cancer Therapeutics	12 months
	Royal Melbourne Hospital, Victoria	
1997	Clinical Research Fellow	
	Breast and Lung Cancer Unit,	12 months
	Royal Marsden Hospital, London, UK	
1998/99	Senior Research Fellow	
	Institute of Cancer Research and the Royal Marsden Hospital	24 months
2000/01	Consultant Medical Oncologist	
	Austin & Repatriation Medical Centre	24 months
2002-16	Consultant Medical Oncologist	
	Royal Melbourne Hospital (2002-2016)	
	Western Hospital (2002-2012)	
	Royal Women's Hospital, Parkville (2008-2010)	
	Epworth-Freemasons Hospital, East Melbourne (2002-	
	Peter MacCallum Cancer Institute, Parkville (2016-	

## Publications

### PAPERS:

1. de Boer R, Grigg A. Adult leukaemia: Making the diagnosis. Aust Fam Physician 23:8 1508-1518, 1994.

2. Cebon J, MacGregor D, Scott A, de Boer R. Immunotherapy of melanoma: Targeting defined antigens. *Australasian Journal of Dermatology* 38 (suppl), S66-S72, 1997.
3. de Boer RH and Basser RL. Pegylated Recombinant Megakaryocyte Growth and Development Factor. *Hematopoietic. Drugs of the Future* 22/9 987-93, 1997.
4. RH de Boer, IE Smith, and NRM. Sacks.. Long Term Survival after Hepatic Resection for Metastatic Breast Cancer. *Eur J Cancer* 34: 1815, 1998.
5. R H de Boer, IE Smith, U Pastorino, MER O'Brien, F Ramage, S Ashley and P Goldstraw. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: A randomised feasibility study justifying a multicentre phase III trial. *Br J Cancer* 79: 1514, 1999.
6. de Boer R, Kiers L, Grigg A. A case of autonomic neuropathy associated with natural killer cell lymphoproliferative disease. *The Journal of Clinical Neuroscience* 6: 61, 1999.
7. RH de Boer, A Saini, SRD Johnston, MER O'Brien, PA Ellis, MW Verrill, JA Prendiville, G Walsh, S Ashley and IE Smith. Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. *The Breast* 9: 149, 2000.
8. Smith IE, Johnston SRD, O'Brien M, Hickish T, De Boer RH, Cirkel D, and Barton C. Continuous low dose oral 5-fluorouracil (5-FU) with eniluracil (776C85) is a clinically effective first-line treatment for patients with advanced breast cancer. *J Clin Oncol* 12: 2378, 2000.
9. RH De Boer, WH. Allum, SR Ebbs, GPH. Gui, SRD. Johnston, NPM. Sacks, G. Walsh, S. Ashley, IE Smith. Multimodality Therapy in Inflammatory Breast Cancer: Is There a Place for Surgery? *Annals of Oncology* 9: 1147-53, 2000.
10. Richard H. de Boer, Loren Roskos, Ellen Cheung, Simon Fox, Russell L Basser, Jennifer Marty, C. Glenn Begely, and Jonathan Cebon. Pharmacokinetic analysis of Pegylated Megakaryocyte Growth and Development Factor in humans. *Growth Factors* 18: 215-26, 2000.
11. RH De Boer, TQ Eisen, PA Ellis, SRD. Johnston, G Walsh, S Ashley and IE Smith. A Randomised Phase II Study of Conventional versus Accelerated Infusional Chemotherapy with Granulocyte Colony-Stimulating Factor Support in Advanced Breast Cancer. *Annals of Oncology* 13: 889, 2002.
12. J Siderov, P Prasad, R de Boer and J Desai. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. *Brit J Cancer* 12-13, 2002.
13. Richard de Boer. Tailoring adjuvant treatment for post-menopausal node-negative breast cancer. *Commentary: Clinical Update. Issue 13*, 2003.
14. S. Wong, M.A. Rosenthal, R. de Boer, M.D. Green, R.M. Fox. Five Years Managing Metastatic Non-Small Cell Lung Cancer: Experience at a Teaching Hospital. *Internal Medical Journal* 34:458-63, 2004.
15. Ross Jennens, Richard de Boer, Louis Irving, David Ball and Mark Rosenthal. Differences of opinion: A survey of knowledge and bias amongst clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. *Chest* 126: 1985-93, 2004.
16. Scott N Holden, Gail Eckhardt, Russell Basser, Mark Rosenthal, Richard de Boer, Danny Rischin, Michael Green, Catherine Wheeler, Alan Barge, Herbert I Hurwitz. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF receptor signaling, in patients with solid, malignant tumors. *Ann Oncol. Aug;16(8):1391-97*, 2005.
17. Raymond Ng, Richard de Boer, and Michael Green. Under-treatment of the elderly with non-small cell lung cancer. *Clinical Lung Cancer. Nov;7(3):168-74*, 2005.

18. Frances Barnett and Richard de Boer. Cancer treatment-induced bone loss: a review. *Asia-Pacific Journal of Clinical Oncology*. 2: 156-66, 2006.
19. Brian H. C. Le, Malcolm R. Buchanan, Christopher Steer, and Richard De Boer. Late Recurrence of Osteosarcoma. *Internal Medicine Journal*. 37(6):420-22, 2007.
20. Allan Lipton, Guenther G. Steger Jazmin Figueroa, Cristina Alvarado, Philippe Solal-Celigny, Jean-Jacques Body, Richard de Boer, Rossana Berardi, Pere Gascon, Katia S. Tonkin, Robert Coleman, Alexander H. G. Paterson, Mark C. Peterson, Michelle Fan,, Amy Kinsey, and Susie Jun. Randomized Active-controlled Phase 2 Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases. *J. Clin Oncol*. Oct 1;25(28):4431-37, 2007.
21. A Chan and R de Boer. Use of trastuzumab for metastatic breast cancer in Australia: inaccurate results and alternative interpretation of findings. *J Clin Oncol*. Dec 10;25(35):5662-63, 2007.
22. Nigel J. Bundred, Ian D. Campbell, Neville Davidson, Richard H. De Boer, Holger Eidtmann, Alain Monnier, Gunter von Minckwitz, Joel C. Miller, Nora L. Schenk, Robert E. Coleman. Effective Inhibition of Aromatase Inhibitor-Associated Bone Loss by Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: ZO-FAST Study Results. *Cancer*. 12, 1001-10, 2008.
23. Field K, Campbell B, De Boer R. Male breast cancer – progress, prognosis and future pathways. *Asia-Pacific Journal of Clinical Oncology*. 4 (1), 6-17, Mar 2008.
24. Allan Lipton, Guenther G. Steger, Jazmin Figueroa, Cristina Alvarado, Philippe Solal-Celigny, Jean Jacques Body, Richard de Boer, Rossana Berardi, Pere Gascon, Katia S. Tonkin, Robert E. Coleman, Alexander H. G. Paterson, Guozhi M. Gao, Amy C. Kinsey, Mark C. Peterson, and Susie Jun. Extended Efficacy and Safety Denosumab in Breast Cancer Patients With Bone Metastases Not Receiving Prior Bisphosphonate Therapy. *Clinical Cancer Research*. 14 (20), Oct 2008.
25. Raymond D Snyder, Frances M Boyle, Arlene Chan, Paul S Craft, Richard de Boer, Paul N Mainwaring, Nicole J McCarthy. Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. *Asia Pacific Journal of Clinical Oncology*. March 2009.
26. Richard de Boer, Yves Humblet, Jürgen Wolf, Lucia Nogová, Klaus Ruffert, Tsveta Milenkova, Robert Smith, Alex Godwood and Johan Vansteenkiste. A Phase I, open-label study of vandetanib (ZACTIMA) with pemetrexed (Alimta) in patients with previously treated NSCLC. *Annals of Oncology*. 20, 486-91, 2009.
27. Kathryn M. Field and Richard H. de Boer. Male breast cancer: A review. *The Asia-Pacific Journal of Oncology & Hematology*. Vol 1, 19-26, March 2009.
28. Arlene Chan; Richard De Boer; Jane Beith; David Grimes; Dusan Kotasek; Nicholas Wilcken. Clinical controversies in breast cancer: A thought leader forum and consensus roundtable. *Asia-Pacific J of Oncology & Hematology*. 1:(3). Sep 1, 2009.
29. Holger Eidtmann; Richard de Boer; Nigel Bundred; Antonio Llombart; Neville Davidson; Patrick Neven; Gunter von Minckwitz; Joel Miller; Nora Schenk; Robert Coleman. Efficacy of Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: 36-month Results of the ZO-FAST Study. *Annals of Oncology*. Nov 21(11):2188-94 2010.
30. Alison T. Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard de Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise Yardley, María Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun. Denosumab Compared with Zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double Blind Study. *J Clin Oncol*. Dec 10;28 (35):5132-9, 2010.

31. Richard de Boer; Michael Clemens; Gabor Renczes; Dusan Kotasek; Jana Prausova; Norbert Marschner; Michael Hedenus; Sameer Doshi; Lisa Hendricks; Anders C Österborg. Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies. *Med Oncol*. Oct 29, 2010.
32. Richard H de Boer, Óscar Arrieta, Chih-Hsin Yang, Maya Gottfried, Valorie Chan, Johann Raats, Filippo de Marinis, Raymond P Abratt, Jürgen Wolf, Fiona H Blackhall, Peter Langmuir, Tsveta Milenkova, Jessica Read and Johan Vansteenkiste. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL) *J Clin Oncol*. Mar 10, 1067-74, 2011.
33. Richard H. de Boer, Arlene Chan, Ben Tran, Nicholas Wilcken. Use of non-anthracycline regimens in early stage breast cancer within Australia. *Asia Pacific J Clinical Oncology*. Mar; 7(1):4-10, 2011.
34. Alison T. Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard de Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise Yardley, María Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun. Denosumab Compared with Zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double Blind Study. Reply to M.S. Aapro. *JCO* May 10, 2011.
35. Alison T. Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard de Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise Yardley, María Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun. Denosumab Compared with Zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double Blind Study. Reply to V. Fusco et al *J Clin Oncol* Jun 10, 2011.
36. Richard De Boer. 2011 International Patient Case Forum: Worldwide Clinical Experience With Lapatinib in Combination With Capecitabine or an Aromatase Inhibitor for the Treatment of HER-2+ Metastatic Breast Cancer. Editorial. *The Oncologist*. July 2011.
37. Hui-Ling Wong and Richard H. De Boer. Vandetanib for the treatment of non-small cell lung cancer. *Expert Opinions in Pharmacotherapy* October, Vol. 12, 14, 2271-78, 2011.
38. M Michael, N Pavlakis, P Clingan, R De Boer, M Johnston, S Clarke. A Multi-Centre Randomized, Open-Label Phase II Trial of Continuous Erlotinib Plus Gemcitabine or Gemcitabine as First-Line Therapy in ECOG PS2 Patients with Advanced Non-Small-Cell Lung Cancer. *Oncol Reports*. 28: 763-67, 2012.
39. Richard H. De Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Arlene Chan, Rebeca Melara, Yining Ye, Henry Adewoye, Robert Sikorski, Peter A. Kaufman. Phase 1b Dose-Finding Study of Motesanib With Docetaxel or Paclitaxel in Patients With Metastatic Breast Cancer. *Breast Cancer Research and Treatment*, Vol 135, 1: 241-52, 2012.
40. Christopher Hart and Richard H. De Boer. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. *OncoTargets & Therapy* 6, 1-7, January 2013
41. Richard H. De Boer. Editorial: Vandetanib in advanced Non Small Cell Lung Cancer: Promise unfulfilled. *Translational Lung Cancer Research*, January 2013.
42. R. Coleman, R. de Boer, H. Eidtmann, A. Llombart, N. Davidson, P. Neven, G. von Minckwitz, H.P. Sleeboom, J. Forbes, C. Barrios, A. Frassoldati, I. Campbell, O. Paija, N. Martin, A. Modi, N. Bundred. Zoledronic Acid for Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole (ZO-FAST Study): Final 60-Month Results. *Annals of Oncology* 24(2): 398-405, February 2013.

43. Rachel Jui-Chi Chang, Katharine Kirkpatrick, Richard H. De Boer and G. Bruce Mann. Does immediate breast reconstruction compromise the delivery of adjuvant chemotherapy? *The Breast* 22, 1: 64-69, February 2013.
44. John F. R. Robertson, Jean Marc Ferrero, Hugues Bourgeois, Hagen Kennecke, Richard de Boer, William Jacot, Jesse McGreivy, Samuel Suzuki, Min Zhu, Ian McCaffery, Elwyn Loh, Jennifer L. Gansert, Peter A. Kaufman. Ganitumab with Either Exemestane or Fulvestrant in Postmenopausal Women with Advanced, Hormone-Receptor-Positive Breast Cancer. *Lancet Oncology* Mar; 14(3): 228-235 March 2013.
45. Charles S. Cleeland, Jean-Jacques Body, Alison Stopeck, Roger von Moos, Lesley Fallowfield, Susan D. Mathias, Donald L. Patrick, Mark Clemons, Katia Tonkin, Norikazu Masuda, Allan Lipton, Richard de Boer, Stefania Salvagni, Celia Tosello Oliveira, Yi Qian, Qi Jiang, Roger Dansey, Ada Braun, Karen Chung. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. *Cancer* Vol 119, 4: 832-38, February 2013
46. Luis Paz-Ares, Beatrix Bálint, Richard H. de Boer, Jan van Meerbeeck, Rafal Wierzbicki, Paul De Souza, Francesco Galimi, Vincent Haddad, Tony Sabin, Yong jiang Hei, Yang Pan, Susan Cottrell, Cheng-Pang Hsu, Rodryg Ramlau. A Randomized Phase 2 Study of Paclitaxel and Carboplatin With or Without Conatumumab for First-Line Treatment of Non-Small-Cell Lung Cancer. *Journal of Thoracic Oncology* 8(3): 29-337, March 2013.
47. Arlene Chan, Charles Su, Richard de Boer, Adam Gajdatsy. Prevalence of epiphora in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. *J. Clin Oncol* 17: 2123-212, June 10, 2013.
48. de Boer RH, Baker C, Speakman D, Chao C, Yoshizawa C and Mann GB. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. *Med J of Aust* 199(3): 205-208 Aug 5, 2013.
49. Richard de Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, White White, Nicholas Wilcken, Nicholas Zdenkowski, and Richard Bell. Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives. *Asia Pacific J of Clin Onc* 10: 15-25, June 2014.
50. Wilcken, Nicholas; Zdenkowski, Nicholas; White Michelle; Snyder, Ray; Pittman, Ken; Mainwaring, Paul; Green, Michael; Francis, Prudence; De Boer Richard; Colosimo, Maree; Chua, Sue; Chirgwin, Jacquie; Beith, Jane; Bell, Richard. Systemic Treatment of HER2-positive Metastatic Breast Cancer: A Systematic Review. *Asia Pacific J of Clin Onc* 10:1-14, June 2014.
51. Arlene Chan, Catherine Shannon, Richard De Boer, Sally Baron-Hay, Andrew Redfern, Astrid Bauwens, Paul Craft, Suzanne Webb, Amanda Townsend, Dusan Kotasek. Phase II, open label trial of lapatinib and vinorelbine in women with previously treated her2 positive metastatic breast cancer. *Asia Pacific J of Clin Onc* 10: 368-375, Dec 2014.
52. Guy Jerusalem, Thomas Bachelot, Carlos Barrios, Patrick Neven, Angelo Di Leo, Wolfgang Janni, Richard de Boer. A New Era of Improving Progression-Free Survival in HR+, HER2-Advanced Breast Cancer With Dual Blockade. *Cancer Treatment Reviews*, 41(2):94-104, Feb 2015. Epub Dec 2014
53. Adam Platt, Paul Elvin, John Morten, Qunsheng Ji, Emma Donald, Chris Womack, Xinying Su, Li Zheng, Amanda Gladwin, The RET Analysis Team, James Vasselli, Jin Soo Lee, Richard de Boer, Roy Herbst. Retrospective evaluation of RET biomarker status and outcome to vandetanib in 4 Phase III randomized NSCLC trials. *BMC Cancer* 15: 171, April 2015.



54. Jean-Jacques Body, Henry G. Bone, Richard H. de Boer, Alison Stopeck, Catherine Van Poznak, Ronaldo Damião, Karim Fizazi, David H. Henry, Toni Ibrahim, Allan Lipton, Fred Saad, Neal Shore, Toshimi Takano, Adam Shaywitz, Ada Braun, Huei Wang, Oswaldo L. Bracco, Paul J. Kostenuik. Hypocalcemia in Patients with Metastatic Bone Disease Treated with Denosumab. *Eur J Can Sep* 51(13):1812-21 2015
55. Ian Krop, Ingrid Mayer, Vinod Ganju, Maura Dickler, Stephen Johnston, Serafin Morales, Denise Yardley, Bohuslav Melichar, Andres Forero-Torres, Soo Chin Lee, Richard de Boer, Katarina Petrakova, Susanne Vallentin, Edith Perez, Martine Piccart, Matthew Ellis, Eric Weiner, Steven Gendreau, Mika Derynck, Mark Lackner, Gallia Levy, Jiaheng Qui, Jing He, Peter Schmid. The FERGI phase 2 study of the PI3K inhibitor pictilisib plus fulvestrant versus placebo plus fulvestrant in patients with oestrogen receptor-positive, aromatase inhibitor-resistant advanced or metastatic breast cancer. *Lancet Oncology*, Jun;17(6):811-21, 2016.
56. Beith, Jane; Burslem, Katie; Bell, Richard; Woodward, Natasha; McCarthy, Nicole; De Boer, Richard; Loi, Sherene; Redfern, Andrew. Hormone receptor positive, HER2 negative metastatic breast cancer: a systematic review of the current treatment landscape. *Asia-Pacific J of Clin Onc*, March; 12:3-18, 2016.
57. Redfern, Andrew; Burslem, Katie; Woodward, Natasha; Beith, Jane; McCarthy, Nicole; De Boer, Richard; Bell, Richard. Hormone receptor positive, HER2 negative metastatic breast cancer: future treatment landscape. *Asia-Pacific J of Clin Onc*, March; 12:19-31, 2016.
58. Steven Limentani; Mario Campone; Thierry Dorval; Giuseppe Curigliano; Richard de Boer; Charles Vogel; Shane White; Thomas Bachelot; Lean Luc Canon; Mary Disis; Ahmad Awada; Martine Berliere; Frederic Amant; Ellis Levine; Wivine Burny; Andrea Callegaro; Pedro Miguel de Susa Alves; Jamila Louahed; Vincent Bricard; Frederic Lehmann. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. *Breast Cancer Res Treat* 156:319–330. 2016
59. Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. *J Clin Oncol*. Apr 1;35(10):1041-1048, 2017.
60. Arlene Chan; Richard De Boer; Albert Gan; Peter Willsher; Richard Martin, Yvonne Zissiadis; Kaye Miller, Astrid Bauwens; Diana Hastrich. Randomised phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study). *Supportive Care in Cancer* 25(12), 3785-3791, 2017
61. Lavinia Tan, Marliese Alexander, Ann Officer, Michael MacManus, Linda Mileshkin, Ross Jennens, Dishan Herath, Richard de Boer, Stephen B Fox, David Ball and Benjamin Solomon. Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC) Published online *Internal Medicine Journal* 24 May 2017.
62. Kenneth Pittman, Yolanda C Antill, Amanda Goldrick, Jeffrey Goh, and Richard H de Boer. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. *Asia-Pacific J of Clin Onc*, August 13; 4, 266–76, 2017
63. Melinda Pattanasri, Kenneth Elder, Carolyn Nickson, Samuel Cooke, Dorothy Machalek, Allison Rose, Arlene Mou, John P. Collins, Allan Park, Richard De Boer, Claire Phillips, Vicki Pridmore, Helen Farrugia and Bruce Mann. Uptake of adjuvant breast cancer treatments recommended by multi-disciplinary meetings *ANZ J Surg* Dec 2017

64. Joanne M Shaw; Jane O'Brien; Susan Chua; Richard De Boer; Rachel Dear; Fran Boyle; Nicholas Murray. Barriers and Enablers to Implementing Scalp Cooling in Australia: A Qualitative Study of Health Professionals' Attitudes to and Experience with Scalp Cooling. *Supportive Care in Cancer*, January Volume 26, 1 pp 305–312, 2018

65. Suzette Delaloge, David Cella, Yining Ye, Marc Buyse, Arlene Chan, Carlos H. Barrios, Franki A. Holmes, Janine Mansi, Hiroji Iwata, Bent Ejlersen, Beverly Moy, Gunter von Minckwitz, Stephen K.L. Chia, Michael Gnant, Snezhana Smichkoska, Audrone Ciceniene, Isil Somali, Noelia Martinez, Sladjana Filipović, Noa Efrat Ben-Baruch, Anil A. Joy, Sven T. Langkjer, Francis Senecal, Richard H. de Boer, Susan Moran, Bin Yao, Richard Bryce, Alan Auerbach, Lesley Fallowfield, and Miguel Martin. . Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2 Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. Submitted *JCO* September 2017

66. Treatment intensity differences after early stage breast cancer (ESBC) diagnosis depending on participation in a screening program. Submitted *Annals of Surgical Oncology* Sept 2017

### Manuscripts in Preparation.

1) De Boer RH, Patterson WK, Beith J, Lynch J, Selva-Nayagam S, Rocchi L, Beer F, Lewis CR. Pegfilgrastim and darbepoetin alfa support dose-dense doxorubicin + cyclophosphamide followed by paclitaxel (AC→T) in early stage breast cancer: the ACCELERATE study.

2) Jessica Day, Bernard Yang, Richard de Boer and Alpha Tsui. Paraneoplastic Cerebellar degeneration and Squamous Cell Carcinoma of Lung: a case report.

3) Bergin A, Stevens M, De Boer RH, and Green M. Vitamin D levels in patients with early stage breast cancer.

4) L. Chin-Lenn, E. Segelov, R.H. De Boer, G.M. Marx T.M. Hughes, N.J. McCarthy, S.C. White, S.S. Foo, J.J. Rutovitz, S. Della-Fiorentina, R. Jennens, Y.C. Antill, D. Tsoi, M.F. Cronk, J.M. Lombard, B.E. Kiely, J.H. Chirgwin, A. Gorelik, G.B. Mann. Indications for, and impact of Oncotype DX on adjuvant treatment recommendations when third party funding is unavailable

### BOOK CHAPTERS:

1 R.H. de Boer and Ian E. Smith. Paraneoplastic Syndromes. In *The Oxford Handbook of Oncology*. Ed Dr J. Cassidy (1998).

2. Ian E Smith and Richard H. de Boer. Primary chemotherapy in operable breast cancer: is mastectomy a redundant operation? In: *Challenges in Breast Cancer*. Blackwell Science, Oxford. Ed Ian Fentiman (1999).

3. Ian E. Smith and Richard. H. de Boer. The role of systemic treatment for primary operable breast cancer. In *ABC of Breast Diseases: 2nd Edition*. BMJ Books. Ed: J

4. Ian E. Smith and Richard. H. de Boer. Paraneoplastic Syndromes Other Than Metabolic. In *The Oxford Textbook of Oncology 2nd Edition* (2001).

### Abstracts:

1. Roberts A, Grigg A, de Boer R, Panuncialman G, Brown G, Street, A, Sinickas V, Sheridan W. A pilot study of pre-emptive intravenous antibiotics after allogeneic bone marrow transplant. Haematology Society of Australia, 1992.
2. de Boer R, Fox S, Hopkins W, Cheung E, Roskos L, Basser R, and Cebon J. Pharmacodynamics of Pegylated Megakaryocyte Growth and Development Factor from a phase I study: effects of platelet count on serum levels and clearance. The International Society for Experimental Haematology Annual Meeting. 1996.
3. de Boer RH Seymour JF, Leyden M, Bhathal P, and Grigg AP. A case report of Hodgkin's disease with idiopathic intrahepatic cholestasis and "vanishing bile duct syndrome". Haematological Society of Australia 1996.
4. de Boer RH, Seymour JF, Fox R. Treatment of Waldenstroms Macroglobulinemia with nucleoside analogues. - Haematological Society of Australia 1996.
5. R. Basser, R. de Boer, P. Mitchell, M. Green, J. Zalberg, J. Cebon, J. Renwick, B. Cohen, D. Menchaca, J. LaBrecque, R. Fox, G. Begley: A randomized study of megakaryocyte growth and development factor (PEG-rHuMGDF) before and after chemotherapy - influence of schedule on clinical effect: early results. ASCO, 1997.
6. J. Cebon, E. Jaeger, M. Marchand, Q. Chen, D. MacGregor, R. de Boer, J. Trapani, H. Jackson, A.M. Hutchins, T. Boon, and A. Knuth: Peptide vaccination for melanoma. Fourth World Congress of Melanoma, Sydney, 1997.
7. Eisen T, Smith IE, de Boer R, Ellis PA, Johnston SRD: A randomised phase II trial of infusional 5FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. 20th Annual SABCS, San Antonio 1997.
8. RH de Boer, IE Smith, TQ Eisen, PA Ellis, SRD Johnston and MW Verrill: A randomised pilot study comparing three weekly epirubicin, cyclophosphamide and continuous infusion 5-FU (ECF) to a two weekly schedule (accelerated) with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer. ASCO 1998.
9. R. Basser, C. Underhill, P. Mitchell, M. Green, I. Davis, J. Cebon, J. Zalberg, R. de Boer, et al. Reduction of thrombocytopenia after multicycle, intensive chemotherapy by megakaryocyte growth and development factor (Peg-rHuMGDF). ASCO Annual Meeting, 1998.
10. RH de Boer, P. Goldstraw, U. Pastorino, MER. O'Brien, F. Ramage, S. Ashley and IE. Smith. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: A randomised feasibility study justifying a multicentre phase III trial.: British Oncology Association Annual Meeting 1998.
11. RH De Boer, TQ Eisen, PA Ellis, SRD Johnston, G Walsh, and IE Smith. A randomised study comparing 3-weekly epirubicin, cyclophosphamide and continuous infusion 5-FU (ECF) to a 2-weekly schedule with G-CSF in advanced breast cancer. British Oncology Association Annual Meeting 1998.
12. RH De Boer, SRD Johnson, M Walton, J Salter, M Dowsett, and M Gore. P53/P21 immunophenotype predicts for resistance to single-agent platinum in ovarian cancer. British Association for Cancer Research Annual Meeting 1999.
13. RH De Boer, A Saini, SRD Johnston, and IE Smith. Infusional combination chemotherapy in inflammatory breast cancer: The Royal Marsden Hospital experience. British Association for Cancer Research Annual Meeting 1999.

14. De Boer RH, Allum WH, Ebbs S, Gui GPH, Sacks NRM, Johnston SRD and Smith IE. Multimodality therapy in inflammatory breast cancer (IBC): is surgery necessary? 7th Nottingham International Breast Cancer Conference 1999.
15. De Boer RH, Johnston SRD, Walton M, Salter J, Dowsett M, and Gore ME. The role of p53 and p21 in determining response to first-line single-agent platinum therapy in epithelial ovarian cancer. 7th International meeting for Gynaecological Malignancies 1999.
16. De Boer R, Allum W, Baum M, Ebbs S, Gui G, Johnston S, Sacks N, and Smith IE. Is surgery necessary in inflammatory breast cancer (IBC)? 22nd SABCS, Dec 1999.
17. De Boer R, Smith IE, Johnston S, O'Brien M, Hickish T, Cirkel D, and Barton C. Continuous low dose oral 5-fluorouracil (5-FU) with eniluracil (776C85) is a clinically effective first-line treatment for patients with advanced breast cancer (ABC).: 22nd SABCS, San Antonio Dec 1999.
18. M Harris, R De Boer, S Ramdave, S Berlangieri, S Knight, CP Clarke, F Daniel, J Cebon, AM Scott, and PL Mitchell. Positron emission tomography (PET) assessment of response to neo-adjuvant chemotherapy in stage II and IIIA non-small cell lung cancer. 9th World Conference on Lung Cancer, Tokyo 2000.
19. Richard De Boer, Paul LR Mitchell, Russell Basser, et al. A Phase II Trial of Escalated Dose Docetaxel with G-CSF Support in Patients with Advanced Breast Cancer.: 23rd SABCS, San Antonio 2000.
20. R Basser, H Hurwitz, A Barge, I Davis, R de Boer, et al. Phase I pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumours. ASCO Annual Meeting, San Francisco May 2001.
21. Cebon J, Castles L, de Boer R, et al. Cancer Vaccination: Recent progress in the immunotherapy of breast cancer.: Annual Scientific Congress. The Royal Australasian College of Surgeons, Canberra May 2001.
22. H Hurwitz, SG Eckhardt, R Basser, R de Boer, M Rosenthal, D Rischin, H Swaisland, M McKinley, C Wheeler. A phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumours. ECCO Lisbon October 2001.
23. R De Boer, P Mitchell, M Feigen, A Bui, A Barling, E Stickland, J Evans, J Ham, S Long J Newton, J Spink, and R Gould. A practice support tool in colorectal cancer management.: COSA Brisbane Nov 2001.
24. PLR Mitchell, A Bui, A Barling, R De Boer, J Spink, S Long, J Newton, C Steele, J Ham, L Stickland, J Evans, and C White. Evidence-based practice: the Austin Bowel Cancer Consortium (ABCC) CSSP project. t: COSA Annual Brisbane Nov 2001.
25. PL Mitchell, M Links, P Galettis, J Desai, A Zimet, R De Boer, I Davis, J Cebon, P De Souza. A Phase 1 and Pharmacokinetic Trial of Oxaliplatin and Gemcitabine in Patients with Solid Tumours.: ASCO, Orlando May 2002.
26. H Hurwitz, SN Holden, SG Eckhardt, R de Boer, D Rischin, M Green, R Basser. Clinical Evaluation of ZD6474, an Orally Active Inhibitor of VEGF Signalling, in Patients with Solid Tumours. Abstract: ASCO, Orlando May 2002.
27. H Gan, M Links, P Galettis, J Desai, A Zimet, R De Boer, I Davis, J Cebon, P De Souza, P Mitchell. A Phase 1 and pharmacokinetic trial of oxaliplatin and gemcitabine in patients with solid tumours: MOGA/FRO National Conference, Adelaide August 2002.
28. PL Mitchell, A Bui, A Barling, M Feigen, R de Boer, M Carter, C Naksook, S Long, J Newton, R Gould, J Evens, L Strickland, J Ham, C white. Supporting Evidence Based medicine and continuous

practice improvement in the cancer clinic.: MOGA/FRO National Conference, Adelaide August 2002.

29.GC. Toner, PL. Mitchell, R. De Boer, P. Gibbs, R. Hicks, AM. Scott, G. McArthur, N. Brega, G. Massimini, P. Scigalla. PET imaging study of SU11248 in patients with advanced malignancies. ASCO, Chicago May 2003.

30.M. Harris, PL. Mitchell, S. Berlangieri, R. De Boer, S. Esler, AM. Scott Response assessment using FDG-PET scanning in patients with non small cell lung cancer (NSCLC) undergoing neoadjuvant chemotherapy.. ASCO Chicago May 2003.

31.Phase II study of SU11248 in patients with advanced malignancies incorporating PET imaging G. Toner, P. Mitchell, R de Boer, P Gibbs, R Hicks, A. Scott, G McArthur, N Brega, G Massimini; T. McCarthy. 2003 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Nov 2003

32.Non small cell lung cancer (NSCLC): are elderly patients being under-treated? R Ng, R de Boer, A Park, I Glaspole, S Knight, M Chao, and M Green. ASCO New Orleans, June 2004.

33.Davidson N, Neven P, Llombart A, Bundred N, Monnier A, DeBoer R, Giardina G, Eidtmann H, Schenk N, Koedam J, Dodion P. Zoledronic acid (ZA) in the prevention of cancer treatment-related bone loss in postmenopausal (PM) women receiving letrozole (L) as adjuvant therapy for early breast cancer (EBC).. St Gallen Meeting January 2005.

34.Professor Nigel Bundred on behalf of the ZO-FAST Trialists' Group. Zoledronic Acid in the Prevention of Cancer Treatment-Induced Bone Loss in Postmenopausal Women Receiving Letrozole as Adjuvant Therapy for Early Breast Cancer (ZO-FAST Trial).. 5th EBCC Nice March 2006.

35.Samuel E. Deprimo, Guy Toner, Paul Mitchell, Richard De Boer, Peter Gibbs, Rodney Hicks, Grant McArthur, Nicoletta Brega, Timothy McCarthy, Carlo Bello. Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies. AACR 2006

36.A. C. Österborg, R. de Boer, M. Clemens, G. Renczes, D. Kotasek, J. Prausova, N. Marschner, M. Hedenus, L. Hendricks, R. Amado. A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks. ASCO Atlanta, June 2006.

37.A Lipton; C Alvarado; R de Boer; GG Steger; KS Tonkin; A Kinsey; M Fan; S Jun. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). ASCO Atlanta, June 2006.

38.R. De Boer, H. Burris, A. Monnier, H. Mouridsen, J. O'Shaughnessy, K. McIntyre, K. Pritchard, I. Smith, D. Yardley, on behalf of the H2H trial steering committee. The Head to Head trial: Letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer.. ASCO Atlanta, June 2006.

39.S. A. Limentani, M. Campone, T. Dorval, E. Tan-Chiu, G. Curigliano, R. De Boer, J.Canon, T. Bachelot, J. Louahed, VG. Brichard. Evaluation of a recombinant HER2 vaccine: induction of specific antibodies, T-cells and preliminary activity in metastatic breast-cancer patients.: ASCO Atlanta, June 2006.

40.S.A. Limentani , M. Campone , T. Dorval, G. Curigliano , S. White, R. De Boer, J.L. Canon, T. Bachelot , F. Cormont , J. Ouahed. A recombinant HER2 protein evaluated for cancer immunotherapy: induction of specific antibodies and T-cells. iSBTc 2006, Los Angeles, October 2006

41. A Lipton, R de Boer, J Figueroa, A Paterson, GG Steger, KS Tonkin, M Fan, A Kinsey, and S Jun. Extended Safety and Efficacy Analysis of Denosumab in Breast Cancer Patients With Bone Metastases Without Prior Bisphosphonate Therapy. 29th SABCS, San Antonio 2006.
42. R de Boer, Y Humblet, J Wolf, L Nogová, K Ruffert, R Smith, A Godwood, T T Milenkova and J Vansteenkiste. Vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer (NSCLC): an open-label, multicenter Phase I study. ASCO, Chicago June 2007.
43. A Lipton, RH de Boer, J Figueroa, A Paterson, GG Steger, K Tonkin, G Gao, AC Kinsey, S Jun. Phase 2 Study of Denosumab in Breast Cancer Patients With Bone Metastases Naïve to Intravenous Bisphosphonate Therapy: Extended Efficacy and Safety Analysis. ASCO Breast Cancer Symposium, September 2007, San Francisco.
44. Richard H De Boer, William Patterson, Jane Beith, Larissa Rocchi, Fiona Beer and Craig Lewis. Delivery of adjuvant dose dense doxorubicin+cyclophosphamide paclitaxel to early stage breast cancer patients with pegfilgrastim and darbepoetin alfa support: interim results from an Australian Phase II study. 30th SABCS San Antonio 2007.
45. Richard De Boer, MD, Holger Eidtmann, MD, Anna Lluch, MD, Garziella Pinotti, MD Joel Miller, PhD, Nora Schenk, , Rosh Dias, MD and Robert Coleman, MD The ZO-FAST Trial: Zoledronic Acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. 30th SABCS San Antonio, 2007.
46. Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Mandy Parson, Ada Braun, Dusan Kotasek. Safety and pharmacokinetics of motesanib diphosphate (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer. 30th SABCS, 2007.
47. S.A Limentani, G. Curigliano, M. Campone, T. Dorval, G. Romieu, E. Tan-Chiu, S. White, R. De Boer, et al. dHER2 cancer immunotherapeutic: Clinical response in breast cancer patients is associated with an induction of functional antibodies and the generation of specific T-cells. 30th SABCS, Dec 2007.
48. Campone M, Limentani SA, Curigliano G, Dorval T, Romieu G, White S, De Boer R, et al. A recombinant HER2 protein evaluated for Cancer Immunotherapy in Breast Cancer: Clinical response is associated with induction of humoral and cellular mediated immune response. 19 th ICAT meeting, Paris, February 2008.
49. Richard de Boer and Arlene Chan. Clinical outcomes of patients with T1N0 breast cancers: how important are biological risk factors? 31st SABCS San Antonio, December 2008.
50. Holger Eidtmann, Nigel Bundred, Richard De Boer, et al.. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. 31st SABCS San Antonio, December 2008.
51. J H Chirgwin, J Lewis, R Woodfield, S R Davis, J Eden and R deBoer. ENHANCE Consultative Group, Melbourne, Australia. Menopause surveillance recommendations for patients with endocrine responsive breast cancer. 31st SABCS December 2008.
52. RH de Boer, Ó Arrieta, M Gottfried, FH Blackhall, J Raats, C-H Yang, P Langmuir, T Milenkova, J Read and J Vansteenkiste. Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). ASCO Orlando June 2009
53. RH de Boer, Ó Arrieta, M Gottfried, FH Blackhall, J Raats, C-H Yang, P Langmuir, T Milenkova, J Read and J Vansteenkiste. Vandetanib plus pemetrexed vs pemetrexed as 2nd-line

therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). World Conference on Lung Cancer, San Francisco August 2009.

54.M Michael, N Pavlakis, P Clingan, R De Boer, M Johnston, S Clarke. A multi-centre randomized, open-label phase II trial of erlotinib plus Gemcitabine or Gemcitabine monotherapy as first-line therapy in ECOG PS2 patients with chemo-naive advanced NSCLC. World Conference on Lung Cancer, San Francisco August 2009.

55.Ananda, S, Quinn, M, De Boer, RH, Gibbs, P. Defining the relationship between rising serum ca 125 levels within the normal range and epithelial ovarian cancer recurrence during surveillance. ESGO 16, Serbia, October , 2009.

56.ECCO-ESMO Sept 2009.

57.Richard de Boer, Peter Kaufman, Shane White, et al. Treatment of locally recurrent, unresectable or metastatic breast cancer with AMG 706 plus paclitaxel or docetaxel: results from a phase 1b study. SABCS December 2009

58.Arlene Chan, Richard de Boer, Charles Su, Adam Gajdatsy, Andrea Provis, Felicity Osmond, Andrew Whyte. Epiphora and eye symptoms in patients treated with docetaxel-based regimens for early stage breast cancer. SABCS 2009.

59.Alison Stopeck, Richard De Boer, Yasuhiro Fujiwara, et al. A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal Related Events in Breast Cancer Patients With Bone Metastases. SABCS Dec 2009.

60.Robert Coleman, Nigel Bundred, Richard de Boer, et al on behalf of the Z-FAST, ZO-FAST, and E-ZO-FAST Study Groups. Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. SABCS Dec 2009.

61. Alison Stopeck, Lesley Fallowfield, Donald Patrick, Charles Cleeland, Richard de Boer, et al. Outcomes in Patients With Metastatic Breast Cancer: Results From a Phase 3 Trial of Denosumab vs Zoledronic Acid. ASCO, June 2010.

62.Quincy S-C Chu, Sang-We Kim, Peter M. Ellis, Linda Mileskin, Richard H. De Boer, et al. BMS-754807, an Oral, Dual IGF-1R/Insulin Receptor (IR) Inhibitor: Initial Results from a Phase I Dose- and Schedule-finding Study in Combination with Carboplatin / Paclitaxel in Subjects with Solid Tumors. EORTC-NCI-AACR, Oct 2010

63.Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W, McGreivy J, Suzuki S, Loh E, Robertson J. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC). SABCS Dec 2010

64.Chan A, Lewis C, de Boer R. Prevalence of Triple Negative Breast Cancer (TNBC) and Its Management in 3 Large Breast Cancer Centres in Australia: A Retrospective Review. SABCS Dec 2010

65.Chang R, Kirkpatrick K, De Boer RH, Mann GB. The Impact of Immediate Breast Reconstruction on Surgical Complications and the Delivery of Adjuvant Chemotherapy. SABCS Dec 2010

66.DeBoer R, Bundred N, Eidtmann H, Llombert A, Neven P, von Minckwitz G, Martin N, Modi A, Coleman R. The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up. SABCS Dec 2010

67. Richard de Boer, Miguel Martin, Günther G Steger, et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases: a number-needed-to-treat analysis. Medical Oncology Group of Australia Annual Meeting August 2011
68. Alison T. Stopeck, Allan Lipton, Miguel Martín, Jean-Jacques Body, Alexander Paterson, Guenther G. Steger, Katia Tonkin, Richard H. de Boer, et al. Effect of Denosumab Treatment for Patients with Breast Cancer and Bone Metastases: Results from the Open-label Extension Treatment Phase III Study. SABCS Dec 2011
69. Fallowfield L, Cleeland CS, Body JJ, Stopeck A, von Moos R, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, et al. Pain severity and analgesic use associated with skeletal-related events in patients with advanced breast cancer and bone metastases. SABCS Dec 2011
70. de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Coleman R. Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. SABCS Dec 2011
71. De Boer RH, Speakman, D, Baker C, Mann GB. Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR+), Node Negative (N0) and Node Positive (N+) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic. SABCS Dec 2011
72. Coleman R, de Boer R, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Bundred N. Influence of delayed zoledronic acid initiation on disease-free survival in postmenopausal women with endocrine receptor-positive early breast cancer receiving adjuvant letrozole: exploratory analyses from the ZO-FAST trial. SABCS Dec 2011.
73. Richard de Boer, Miguel Martin, Günther G Steger, et al. A number-needed-to-treat analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases. International Symposium on Oncology Pharmacy Practice, Melbourne, May 2012.
74. Richard De Boer et al. Pain in Patients with Metastatic Breast Cancer: Results from a phase III Trial of Denosumab versus Zoledronic acid. Medical Oncology Society of Australia Annual Meeting Brisbane August 2012
75. Richard de Boer et al. Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: A Pre-Specified Two Year Open-Label Extension Treatment Phase of a Pivotal Phase III Study Medical Oncology Society of Australia, Annual Meeting Brisbane August 2012.
76. Bent Ejlersen, Guy Jerusalem, Sara Hurvitz, Richard de Boer, Tetiana Taran, Tarek Sahmoud, Howard Burris. Everolimus plus exemestane versus everolimus or capecitabine monotherapy in breast cancer: BOLERO-6. St Gallen Meeting Switzerland March 2013.
77. Adam Platt, Paul Elvin, John Morten, Qunsheng Ji, Emma Donald, Chris Womack, Xinying Su, Li Zheng, Amanda Gladwin, James Robert Vasselli, Jin Soo Lee, Richard H. De Boer, Roy S. Herbst. Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. ASCO June 2013, A8045.
78. Allan Lipton, Fred Saad, Catherine H. Van Poznak, Janet Elizabeth Brown, Alison Stopeck, Karim Fizazi, David H. Henry, Neal D. Shore, Ingo J. Diel, Katia Sonia Tonkin, Richard H. De Boer, Huei Wang, Ada H. Braun. Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials. ASCO Jun 2013, A9640.



79. Jean-Jacques Body, Allan Lipton, David H. Henry, Alison Stopeck, Karim Fizazi, Henry G. Bone, Fred Saad, Catherine H. Van Poznak, Richard H. De Boer, et al. Hypocalcemia in patients with metastatic bone disease receiving denosumab. ASCO Jun 2013, A9628.
80. Janet E Brown, Fred Saad, Alison Stopeck, Karim Fizazi, David Henry, Ingo Diel, Richard De Boer, Huei Wang, Ada Braun. Risk Factors for Developing Osteonecrosis of the Jaw (ONJ) in Patients Receiving Denosumab or Zoledronic Acid for Bone Metastases: Results from Three Phase 3 Trials. ECC Sept 2013.
81. Richard H. de Boer, Jean-Jacques Body, Allan Lipton, et al. Hypocalcaemia in Patients With Metastatic Bone Disease (MBD) Receiving Denosumab. COSA Adelaide, Nov 2013
82. B Zhang, Hui-li Wong, D Gunawardana, P Parente, R de Boer, A Barling, P Antippa, R Wong. Adjuvant chemotherapy in resected Stage IB-III non small cell lung cancer. ELCC March 2014.
83. Guy Jerusalem, Thomas Bachelot, Carlos Barrios, Fabrice André, Patrick Neven, Angelo Di Leo, Wolfgang Janni, Richard de Boer. A new era of improving progression-free survival in HR+, HER2- advanced breast cancer with dual blockade. EBCC March 2014.
84. David R. Spiegel, Fred R. Hirsch, Richard De Boer, et al. Randomized, Double-blind, Multicenter, Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer. ASCO Jun 2014.
85. Jean-Jacques Body, Henry G. Bone, Catherine Van Poznak, Richard de Boer, et al. Risk Factors for Hypocalcemia in Patients With Cancer Receiving Denosumab. ESMO Sept 2014.
86. Woodward N, De Boer RH, Redfern A, Von Neumann-Cosel V, Heath RM, Beith J. An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). SABCS Dec 2014
87. Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S, de Boer R, et al The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results. SABCS Dec 2014
88. Juric D, Hamilton E, Garcia Estévez L, De Boer RH, Mayer I, Campone M, Asano S, Bhansali S, Zhang V, Hewes B, Munster. Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2- breast cancer: Safety, preliminary efficacy and molecular analysis. SABCS San Antonio Dec 2014.
89. Allan Lipton, Alison Stopeck, Jean-Jacques Body, Roger von Moos, Richard De Boer, Andrea Paiva Gadelha Guimarães, Katia Tonkin, Yasuhiro Fujiwara, Li Zhu, Douglas Warner. Turnover Marker Levels and Clinical Outcomes in Patients With Breast Cancer and Bone Metastases Treated With Bone Antiresorptive Therapies. SABCS San Antonio Dec 2015
90. Joyce O'Shaughnessy, Denise A. Yardley, - Howard A. Burris, Richard De Boer, Dino Amadori, Kristi McIntyre, Bent Ejlersen, Michael Gnant, Walter Jonat, Kathleen I. Pritchard, Mitch Dowsett, Lowell Hart, Susan Poggio, Pinuccia Valagussa, 15 Hervé Salomon, 16 Barbara Wamil. Randomized Phase 3 Trial of Adjuvant Letrozole vs Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Efficacy and Safety Results of the Femara vs Anastrozole Clinical Evaluation (FACE) Trial. SABCS San Antonio Dec 2015
91. Dejan Juric, Roohi Ismail-Khan, Mario Campone, Laura García-Estévez, Carlos Becerra, Richard De Boer, Erika Hamilton, Ingrid A. Mayer, Rina Hui, Kate I. Lathrop, Lorenzo Rossi, Shizuka Asano, Suraj G. Bhansali, Vickie Zhang, Becker Hewes, Pamela Munster. Phase Ib Study of Ribociclib and Alpelisib and Letrozole in ER+, HER2- Advanced Breast Cancer: Safety, Preliminary Efficacy, and Molecular Analysis SABCS San Antonio Dec 2015.

92. ASCO Novartis

93. TABITHA - A Prospective Multi-Site Registry capturing Treatment and Outcome data in the Metastatic HER2-Positive Breast Cancer Patient MOGA August 2016

Major Oral Presentations:

1) British Oncology Association, 1998

Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: A randomised feasibility study justifying a multicentre phase III trial

2) British Oncology Association, 1998

A randomised study comparing 3-weekly epirubicin, cyclophosphamide and continuous infusion 5-FU (ECF) to a 2-weekly schedule with G-CSF in advanced breast cancer

3) Weekend Oncology Workshop, September 2001

Anti-angiogenic agents – current status

4) Australian and New Zealand Breast Cancer Trials Group Annual Meeting, July 2003

New chemotherapy agents in breast cancer

5) National Cancer Conference of Thailand, November 2003

Update on targeted treatment in breast cancer

6) Australian and New Zealand Breast Cancer Trials Group Annual Meeting, July 2004

Testing Targeted Therapies in Advanced Breast Cancer

7) Breast Cancer: From Bench to Bedside and Beyond: Sydney Symposium Sept 2005

Challenges in the use of chemotherapy agents

8) Philippine Medical Oncology Annual Meeting: October 2005

Update on Aromatase Inhibitors and Skeletal Wellbeing

9) Cochrane Breast Cancer Group: Decision making in breast cancer: October 2005

Aromatase Inhibitors: Results of latest trials and review of toxicity

10) Breast Cancer Thought Leaders Meeting: Paris November 2005.

Does choice of Taxane matter?

11) New Frontiers in Endocrine Therapy for Breast Cancer: Seoul, Korea April 2006.

BIG 1-98 Key Clinical Data:

12) Singapore/Malaysia Oncology Societies Joint Meeting June 2006

Optimising adjuvant endocrine therapy in the management of early breast cancer.

13) Australian Lung Cancer Society Annual Meeting, Cairns, June 2006

ASCO 2006: Update on Lung Cancer

14) Asia-Pacific Breast Cancer Research Summit, Cairns July 2006

Bone Health Management - Z-FAST and ZoFAST

15) Asia-Pacific Breast Cancer Research Summit, Cairns July 2006

FACE: Is there a difference between aromatase inhibitors?

16) FACE Investigators Meeting. ASCO Chicago, June 2007

Distant Disease Free Survival: A Surrogate for Overall Survival?

17) Docetaxel in early-stage BC: translating clinical trial evidence into practice. July 2007.  
Management of the 'low risk' HER2 patient.

18) 1st KL International Breast & Colorectal Cancer Congress, August 2007

Optimal Chemotherapy for High Risk / Node Negative Breast Cancer

19) 1st KL International Breast & Colorectal Cancer Congress, August 2007.

Which Patients with ER Positive Early Breast Cancer Should Receive Chemotherapy

20) Poster Discussion Session San Antonio Breast Cancer Symposium December 2007.

24 mth results of the ZO-FAST study

20) Lapatinib Launch meeting, Seoul, Korea March 2008

21) Medical Oncology Group of Australia Conference August 2008

Best of Australia and New Zealand research: The ZO-FAST trial: 24 month BMD results

22) Global Bone health Tour – Stockholm, Moscow, Istanbul November 2008

Bisphosphonates in the treatment of bone metastases: Clinical use and standards of care

23) Biennial St Vincent's Hospital breast cancer Update Symposium – Melbourne February 2009.  
Menopausal Surveillance in breast Cancer patients

24) Oncology Network and Exchange meeting - Zurich March 2009. After progression on ErbB2-targeted therapy, what are the current treatment options?

25) VIII International Meeting on Cancer Induced Bone Disease – Sydney March 2009. Evidence of the Antitumor Activity of Bisphosphonates in the Adjuvant and Metastatic Setting

26) ZEAL Investigators meeting – Dallas March 2009. Results of the Vandetanib plus Pemetrexed phase III study in advanced NSCLC (ZEAL)

27) Poster Discussion Session - ASCO Orlando June 2009. Results of randomised phase III study of Vandetanib plus Pemetrexed in second line NSCLC (ZEAL)

28) ZENITH meeting, Osaka Japan July 2009. Update and future perspectives of bisphosphonate therapy

29) ANZBCTG Annual meeting Darwin July 2009. Potential role of bisphosphonates for treatment and prevention of breast cancer

30) Oral Presentation, World Conference on Lung Cancer, San Francisco August 2009. Results of randomised phase III study of Vandetanib plus Pemetrexed in second line NSCLC (ZEAL)

31) Poster Discussion Session San Antonio Breast Cancer Symposium December 2009.

Treatment of locally recurrent, unresectable or metastatic breast cancer with AMG 706 plus paclitaxel or docetaxel: results from a phase 1b study

32) Clinical Symposia held in conjunction with the SABCS 2009.

Update on Zoledronic acid in early breast cancer

33) Symposium held as part of the Asian Oncology Summit, Bali March 2010

Controversies in management of ErbB2 positive metastatic breast cancer.

34) APOC meeting. Hong Kong July 2010

Updates and New Perspectives in Node-Positive Early Breast Cancer

35) Bone and Cancer Academy Tour, China, Hong Kong, Taipei August 2010

The expanding role of bisphosphonates in the adjuvant setting

36) Medical Oncology Group of Australia Annual meeting, Sydney August 2010.

Incidence of Skeletal-related Events (SREs) in Breast Cancer Patients with Bone Metastases: Denosumab versus Zoledronic Acid

37) Australian Lung Cancer Conference. October 2010

Non-EGFR-targeted therapies: Other targets in lung cancer

38) Australian Breast Cancer Nurses Annual Conference. Feb 2011

Update on management of Breast Cancer

39) Genomic Health Asian Oncology Leaders Forum, Hong Kong April 2011

Update on clinical utility studies with Oncotype DX

40) 2nd Asian Oncology Summit, Hong Kong April 2011

Strategies for overcoming HER2 resistance in breast cancer

41) Medical Oncology Group of Australia Annual Meeting. Adelaide, August 2011

Best of ASCO 2011: Lung Cancer Update

42) Australian Society for Breast Disease (ASBD) Biennial Meeting, Melbourne October 2011

Predictive Assays – will these become routine?

43) Private Cancer Physicians of Australia – Trainees weekend workshop October 2011

Update on systemic therapy for Lung Cancer

44-46) The 16th Annual Scientific Symposium of the Hong Kong Cancer Institute November 2011

i) Biomarkers for Anti-HER2 Therapies

ii) Practical Application of Genomics in Early Stage Breast Cancer

iii) New Horizons in the Management of Bone Metastasis and New Horizons in the Management of Bone Metastasis and Breast Cancer

47) San Antonio Breast Cancer Symposium December 2011 –

Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST.

48) 10th Annual HOTT meeting March 2012

Targeting NSCLC Treatment – The role of molecular selection – The Reality

49) Speaker Tour Taiwan March 2012

Optimizing Adjuvant Therapy in Node-Negative Breast Cancer

50) MOGA annual meeting Brisbane August 2012

i) Pain in Patients with Metastatic Breast Cancer: Results from a phase III Trial of Denosumab versus Zoledronic acid;

ii) Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: A Pre-Specified Two Year Open-Label Extension Treatment Phase of a Pivotal Phase III Study

51) BCNA annual meeting Sydney October 2012

Bone Health and Breast cancer

52) Sydney International Breast Cancer Congress October 2012

i) Update of therapies for Metastatic HER2 positive Breast cancer

ii) What does Genomic Profiling Provide Beyond Traditional Pathologic Markers?

53) Philippine Society of Medical Oncology Annual Convention October 2012

i) The Value of Building a Multidisciplinary HER-2 Testing Team for Optimum Patient Care in Adjuvant Breast Cancer,

ii) Breast Cancer in the Elderly – A Medical Oncologists perspective,

iii) RANK Ligand-targeted Therapy: A Novel Approach in Bone Health Management for Breast Cancer Patients

54) Annual Scientific Meeting of the Hong Kong College of Radiologists October 2012

Bone-Directed Therapy: Improving Clinical Outcomes in Patients with Solid Tumours

55) Xgeva Launch Symposium Singapore Nov 2012

New approaches to managing Bone Mets and Preventing SREs

56) Medical Oncology Society of Malaysia Collaborative Meeting, Penang August 2013

Advancing The Science of Bone Targeted Therapy for Bone Metastases in Breast Cancer

57-59) Australian Society for Breast Disease (ASBD) Biennial Meeting, Cairns September 2013

i) Breast cancer in the older woman

ii) Breasts, bones and bisphosphates

iii) Genomic Assays in Breast Cancer - A Step towards Personalised Medicine Capturing Tumour Biology Beyond Traditional Factors

60) Personalizing Breast Cancer Treatment: Redefining the Paradigm - 2013 Oncology Leaders Summit Geneva Switzerland Oct 2013.

Research Update: Ongoing clinical trials targeting key crosstalk pathways in HR+ advanced breast cancer

- 61) 3rd Asia – Pacific Breast Cancer Summit, Singapore March 2014: The Great Debate - 34 Year Old Female, pT2N0M0, IDC, Grade 2, Hormone pos, HER2--. Is There a Role for Oncotype?
- 62-63) Asia Pacific Oncology Conference, Hong Kong, July 2014
- i) Highlights From ASCO 2014/SABCS 2013: Which Were Practice-Changing Studies?
- ii) Adjuvant Anthracyclines in Breast Cancer: Which patients require and benefit?
- 64-66) Visiting Professors Programme, McGill University, Quebec and Montreal, Canada, September 2014
- i) What's new with bone targeted agents and practical management of potential side effects and toxicities
- ii) Adjuvant Therapy Selection for Young Breast Cancer Patients / Management of the low risk HER2 positive patient
- iii) New agents in the management of endocrine resistance in metastatic breast cancer
- 67) Update on the Role of Genomics in the Treatment of Breast Cancer, Macau Oct 2014.
- Genomic Assays in Personalizing Adjuvant Systemic Therapy in Breast Cancer: Medical Oncologist's Perspective
- 68) Clinical Oncology Society of Australia (COSA) Annual Meeting, Melbourne Dec 2014:
- Best of the Best Clinical Session: Risk Factors for Hypocalcaemia
- 69) 4th Asia – Pacific Breast Cancer Summit, Brisbane March 2015
- The Great Platinum Debate: Should Platinum's be Standard of Care in Early Stage Breast Cancer?
- 70) 1st CoBRA Controversies in Breast Cancer meeting, Melbourne October 2015:
- That all patients with HER2 positive disease should receive anti-HER2 therapies.
- 71) HER2 Innovation Day, Bangkok, Thailand, March 2016:
- Dual Blockage sets a new standard of care in 1st line HER2 positive MBC
  - Evolving therapy in 2nd line HER2 positive MBC
- 72) 2nd CoBrCa Controversies in Breast Cancer meeting, Barcelona, September 2016:
- Practical use of bone-targeted agents: Can we avoid hypocalcaemia and osteonecrosis of the jaw?
  - Debate: That all TNBC should receive a platinum agent
- 73) Bone Integrity Speaker Tour, Singapore and Taipei, November 2016
- The importance of bone integrity through the breast cancer continuum
  - Prevention of SREs patients with in metastatic lung cancer
- 74) Hochiminh Cancer Conference, Vietnam, December 2016
- Cancer Immunotherapy- The new hope for cancer patient
  - Immuno- oncology therapy in Lung cancer - from research to clinical practice
- 75) Novartis Satellite Symposium "Expanding Horizons: Current and Emerging Treatment Options for Breast Cancer, St Gallen Meeting, Vienna, March 2017
- First Light: Future Innovations in Treatment of HR+ Breast Cancer

76) Oncology Dinner meeting, Perth, April 2017

Optimising Patient Outcomes in HER2+ mBC

77) Role of Internist in Cancer Management Meeting, Jakarta, May 2017

An Update of the Keynote 010 and 024 trials in advanced NSCLC

78) Australasian Lymphology Association Annual Meeting, Melbourne, May 2017

The influence of chemotherapy on lymphedema

79) ANZ Breast Cancer Trials Group Annual Scientific Meeting, Melbourne, July 2017

Bone Targeted therapy in early stage breast cancer

Supportive Care in Cancer,